Related Experiment Video
Updated: Oct 4, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the
Rameez Zaman1, Elliott Goldberg1, Naseem Zomorodi1
1Neurology, Penn State College of Medicine, Hershey, USA.
Abstract:
Dalfampridine is a drug used to improve walking in multiple sclerosis (MS) patients. Approved in 2010, it is contraindicated in patients who have a history of seizures and/or renal disease. In this case report, we present a patient who did not have either of these contraindications yet had a seizure episode with the only contributing factor being the use of dalfampridine.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation
Drug Dosing: Geriatric Patients
Drug Therapy
Antianxiety Medications
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring: Overview and Classification

